At present, a growing body of evidence has illustrated that S100A8 and its heterodimeric partner S100A9 in the S100 family are expected to not only be biomarkers to evaluate the prognosis of patients with MI (Morrow et al., 2008) but also provide new ideas for patient treatment, opening a novel field of MI research. This evidence concerns the gene S100A1 and myocardial infarction.